ClinicalTrials.gg

Program

D-2570

A development code. Also written as “D-2570 Tablet”, “D-2570 Dose 1” and “D-2570 Dose 2”.

Its studies are mostly in Psoriasis · Renal Insufficiency · Colitis, Ulcerative · Vitiligo · Lupus Erythematosus, Systemic, led by InventisBio.

Furthest: phase 3, since Aug 12, 202513 company-led studies, 11 open or runningNext primary completion: Nov 21, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InventisBio1311 open or runningphase 3since Aug 12, 2025Jan 30, 2024Nov 21, 2026phase 1 · NCT07715175

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 30, 2024First study: phase 2 study in Plaque PsoriasisFirst studyNCT06278350 · 161 enrolled · China
  2. Nov 4, 2024Phase 1 study in HealthyNCT07275775 · 100 enrolled · China
  3. May 19, 2025Phase 2 study in Colitis, UlcerativeNCT07035041 · 120 enrolled · China
  4. Aug 12, 2025Phase 3 study in Plaque PsoriasisNCT07130604 · 390 planned · China
  5. Nov 12, 2025Phase 1 study in Healthy VolunteerNCT07270783 · 36 enrolled · United States
  6. Dec 12, 2025Phase 3 study in Plaque PsoriasisNCT07326813 · 477 planned · China
  7. Dec 16, 20252 phase 2 studiesNCT07311200, NCT07315061
  8. Mar 18, 2026Phase 2 study in PsoriasisNCT07489885 · 75 planned · United States
  9. May 28, 2026Phase 2 study in VitiligoNCT07625891 · 160 planned · China
  10. Jul 13, 20262 phase 1 studiesNCT07715175, NCT07715149
  11. Sep 22, 2026Phase 1 study in Healthy SubjectsNCT07875842 · 60 planned · China

Ahead

  1. Nov 21, 2026Primary completion: phase 1 study in Renal InsufficiencyNCT07715175
  2. Dec 31, 2026Primary completion: phase 1 study in Healthy SubjectsNCT07875842
  3. Jul 12, 2027Primary completion: phase 3 study in Plaque PsoriasisNCT07326813
  4. Jul 28, 2027Primary completion: phase 3 study in Plaque PsoriasisNCT07130604

TargetBeta

TYK2 →read by rule
“D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain”study text, by rule · the study

Other programs on TYK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
deucravacitinibruleBristol-Myers Squibbphase 460
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
HS-10374Hansoh Pharmaceutical Groupphase 36
TQH3906Sino Biopharmaceuticalphase 36
FXS5626Fosun Pharmaphase 33
TYK2 Inhibitorruleusynova-pharmaceuticals-ltdno phase1

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07875842Healthy Subjects · China1Not yet recruitingDec 31, 202660
NCT07715175Renal Insufficiency · China1RecruitingNov 21, 202640
NCT07715149Healthy Adult Participants · China1RecruitingOct 31, 202624
NCT07625891Vitiligo · China2RecruitingNov 2027160
NCT07489885Psoriasis · United States2RecruitingAug 202775
NCT07315061Arthritis, Psoriatic · China2RecruitingAug 15, 2027222
NCT07311200Active Systemic Lupus Erythematosus · China2RecruitingAug 31, 2028120
NCT07326813Plaque Psoriasis · China3RecruitingJul 12, 2027477
NCT07270783Healthy Volunteer · United States1Active, not recruitingJun 25, 202636
NCT07130604Plaque Psoriasis · China3RecruitingJul 28, 2027390
NCT07035041Colitis, Ulcerative · China2Active, not recruitingJul 30, 2026120
NCT07275775Healthy · China1CompletedJun 23, 2025100
NCT06278350Plaque Psoriasis · China2CompletedNov 1, 2024161

How it is read

Names in the registry

  • “D-2570”, 10 entries
  • “D-2570 Tablet”, 2 entries
  • “D-2570 Dose 1”, 1 entry
  • “D-2570 Dose 2”, 1 entry
  • “D-2570 Dose 3”, 1 entry

Codes read as this program: D2570.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.